Brokerages Set Orthofix Medical Inc. (NASDAQ:OFIX) Price Target at $14.75

Posted by Brian Himes on Aug 27th, 2026

Orthofix Medical Inc. (NASDAQ:OFIX – Get Free Report) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $14.75.

A number of equities analysts have commented on the company. Stifel Nicolaus lowered their price objective on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Barrington Research increased their target price on Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Friday, July 17th. Finally, Canaccord Genuity Group dropped their price target on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, August 10th.

Check Out Our Latest Research Report on OFIX

Orthofix Medical Stock Performance

NASDAQ OFIX opened at $9.75 on Friday. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $397.12 million, a P/E ratio of -6.33 and a beta of 0.68. Orthofix Medical has a 12-month low of $8.85 and a 12-month high of $16.99. The firm has a 50-day moving average price of $10.65 and a two-hundred day moving average price of $11.40.

Orthofix Medical (NASDAQ:OFIX – Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical device company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.02. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The company had revenue of $210.93 million for the quarter, compared to analysts’ expectations of $209.28 million. Analysts anticipate that Orthofix Medical will post -1.29 earnings per share for the current year.

Insider Buying and Selling at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,670 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.38, for a total transaction of $34,424.60. Following the completion of the sale, the insider owned 66,330 shares of the company’s stock, valued at approximately $622,175.40. This represents a 5.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OFIX. Juniper Investment Company LLC raised its stake in Orthofix Medical by 23.3% during the fourth quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock worth $53,217,000 after acquiring an additional 663,278 shares in the last quarter. Engine Capital Management LP boosted its stake in shares of Orthofix Medical by 3.2% in the 1st quarter. Engine Capital Management LP now owns 4,390,779 shares of the medical device company’s stock valued at $50,362,000 after purchasing an additional 137,858 shares in the last quarter. Paradigm Capital Management Inc. NY acquired a new stake in shares of Orthofix Medical in the 2nd quarter valued at approximately $30,167,000. Global Strategic Investment Solutions LLC bought a new stake in shares of Orthofix Medical during the 1st quarter valued at approximately $664,000. Finally, Great Lakes Advisors LLC bought a new stake in shares of Orthofix Medical during the 2nd quarter valued at approximately $1,236,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

About Orthofix Medical

(Get Free Report)

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.